Published in Drug Metab Dispos on February 02, 2010
Effectiveness of Ketamine in Malignant Neuropathic Pain Relief (KETA-1) | NCT01951911
Effects of mitragynine and 7-hydroxymitragynine (the alkaloids of Mitragyna speciosa Korth) on 4-methylumbelliferone glucuronidation in rat and human liver microsomes and recombinant human uridine 5'-diphospho-glucuronosyltransferase isoforms. Pharmacognosy Res (2015) 0.77
Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat. Br J Pharmacol (2015) 0.77
The Relationship Between Creatine and Whey Protein Supplements Consumption and Anesthesia in Rats. Anesth Pain Med (2016) 0.75
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis (2006) 7.36
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents (2005) 4.71
Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol (2011) 3.80
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis (2013) 3.49
Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics (2005) 2.98
Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol (2004) 2.71
Comparison of three optical coherence tomography scanning areas for detection of glaucomatous damage. Am J Ophthalmol (2005) 2.54
Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother (2003) 2.42
Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother (2004) 2.36
Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother (2003) 2.30
Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer (2002) 2.18
Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother (2002) 2.02
Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother (2009) 1.83
The performance of compartmental and physiologically based recirculatory pharmacokinetic models for propofol: a comparison using bolus, continuous, and target-controlled infusion data. Anesth Analg (2009) 1.82
Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother (2008) 1.75
Wide excision or Mohs micrographic surgery for the treatment of primary dermatofibrosarcoma protuberans. Am J Clin Oncol (2010) 1.72
Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant (2006) 1.70
Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res (2007) 1.68
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother (2012) 1.59
Human udp-glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab Dispos (2004) 1.51
Subacute toxicity of colistin methanesulfonate in rats: comparison of various intravenous dosage regimens. Antimicrob Agents Chemother (2008) 1.46
Predictive value of sputum gram stain for the determination of appropriate antibiotic therapy in ventilator-associated pneumonia. J Trauma (2007) 1.42
Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) "probes" for human udp-glucuronosyltransferases. Drug Metab Dispos (2005) 1.41
Trimethylamine: metabolic, pharmacokinetic and safety aspects. Curr Drug Metab (2005) 1.40
The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol (2013) 1.39
Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab Dispos (2003) 1.30
Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet (2012) 1.30
Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: an MRI study. Chest (2007) 1.27
In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos (2006) 1.20
Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas. Gastroenterology (2012) 1.15
Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. J Steroid Biochem Mol Biol (2007) 1.15
Determination of colistin in human plasma, urine and other biological samples using LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.13
Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol (2006) 1.12
A plasma microRNA panel for early detection of colorectal cancer. Int J Cancer (2014) 1.11
The cardioprotective effect of isosteviol on rats with heart ischemia-reperfusion injury. Life Sci (2006) 1.09
Intratumoral IL-17⁺ cells and neutrophils show strong prognostic significance in intrahepatic cholangiocarcinoma. Ann Surg Oncol (2012) 1.08
Human miR-1228 as a stable endogenous control for the quantification of circulating microRNAs in cancer patients. Int J Cancer (2014) 1.07
Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics (2007) 1.07
Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'. ACS Chem Biol (2014) 1.06
Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther (2007) 1.06
The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases. Drug Metab Dispos (2008) 1.05
Oral L-carnitine: metabolite formation and hemodialysis. Curr Drug Metab (2006) 1.05
Using Dynamic 99mT c-GSA SPECT/CT fusion images for hepatectomy planning and postoperative liver failure prediction. Ann Surg Oncol (2014) 1.03
Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase. J Biol Chem (2008) 1.02
Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers. Basic Clin Pharmacol Toxicol (2008) 1.02
In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. Eur J Clin Pharmacol (2009) 1.02
Renal disposition of colistin in the isolated perfused rat kidney. Antimicrob Agents Chemother (2009) 1.02
Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos (2005) 1.01
S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol (2005) 1.01
An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol (2006) 1.00
Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites. Mol Pharmacol (2008) 0.98
Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst (2003) 0.98
Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol (2014) 0.97
Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. Int J Cancer (2005) 0.95
Translational pain research: evaluating analgesic effect in experimental visceral pain models. World J Gastroenterol (2009) 0.95
Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime? Br J Clin Pharmacol (2006) 0.95
The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos (2008) 0.95
Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol (2010) 0.95
Determination of the reference range of endogenous plasma carnitines in healthy adults. Ann Clin Biochem (2008) 0.94
The neuroprotective effects of isosteviol against focal cerebral ischemia injury induced by middle cerebral artery occlusion in rats. Planta Med (2008) 0.94
Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol (2006) 0.94
Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol (2004) 0.93
High-performance liquid chromatography spectrometric analysis of trans-resveratrol in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.92
Pharmacokinetics of fentanyl after subcutaneous administration in volunteers. Eur J Anaesthesiol (2010) 0.92
ERM protein moesin is phosphorylated by advanced glycation end products and modulates endothelial permeability. Am J Physiol Heart Circ Physiol (2009) 0.92
Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochem Pharmacol (2006) 0.91
Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol (2011) 0.91
Lymph Node Ratio-based Staging System Outperforms the Seventh AJCC System for Gastric Cancer: Validation Analysis With National Taiwan University Hospital Cancer Registry. Am J Clin Oncol (2017) 0.91
Comparison of linear and nonlinear classification algorithms for the prediction of drug and chemical metabolism by human UDP-glucuronosyltransferase isoforms. J Chem Inf Comput Sci (2003) 0.90
Endogenous plasma carnitine pool composition and response to erythropoietin treatment in chronic haemodialysis patients. Nephrol Dial Transplant (2008) 0.90
In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans. J Pharmacol Exp Ther (2010) 0.90
Depression is associated with worse patency and recurrent leg symptoms after lower extremity revascularization. J Vasc Surg (2007) 0.90
Patients with depression are at increased risk for secondary cardiovascular events after lower extremity revascularization. J Gen Intern Med (2008) 0.90
Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther (2004) 0.89
In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. Br J Clin Pharmacol (2002) 0.89
The novel UDP glycosyltransferase 3A2: cloning, catalytic properties, and tissue distribution. Mol Pharmacol (2010) 0.89
In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol (2007) 0.89
Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol Pharmacol (2004) 0.88
L-carnitine supplementation in the dialysis population: are Australian patients missing out? Nephrology (Carlton) (2008) 0.88
The utility of the Venous Clinical Severity Score in 682 limbs treated by radiofrequency saphenous vein ablation. J Vasc Surg (2007) 0.87
Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia. Cancer Chemother Pharmacol (2012) 0.87
The "albumin effect" and in vitro-in vivo extrapolation: sequestration of long-chain unsaturated fatty acids enhances phenytoin hydroxylation by human liver microsomal and recombinant cytochrome P450 2C9. Drug Metab Dispos (2008) 0.87
The glucuronidation of R- and S-lorazepam: human liver microsomal kinetics, UDP-glucuronosyltransferase enzyme selectivity, and inhibition by drugs. Drug Metab Dispos (2013) 0.87
Prediction of metabolism by cytochrome P450 2C9: alignment and docking studies of a validated database of substrates. J Med Chem (2008) 0.86
A population model of early rheumatoid arthritis disease activity during treatment with methotrexate, sulfasalazine and hydroxychloroquine. Br J Clin Pharmacol (2015) 0.86
Antihyperglycemic effects of baicalin on streptozotocin - nicotinamide induced diabetic rats. Phytother Res (2011) 0.86
Reliability and validity of indices of hand-grip strength and endurance. Aust Occup Ther J (2011) 0.86
Quality of requests for serum digoxin concentrations: experience from an Australian regional health service. Br J Clin Pharmacol (2006) 0.86
Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.86
Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies. J Pharmacol Exp Ther (2014) 0.85
The glycosidation of xenobiotics and endogenous compounds: versatility and redundancy in the UDP glycosyltransferase superfamily. Pharmacol Ther (2012) 0.85
Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics (2002) 0.85
Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation. J Pharmacol Exp Ther (2007) 0.85
Effects of tetramethoxystilbene on hormone-resistant breast cancer cells: biological and biochemical mechanisms of action. Cancer Res (2007) 0.85
Dashboard systems: implementing pharmacometrics from bench to bedside. AAPS J (2014) 0.84